The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| BIOHAVEN LTD | COM | G1110E107 | 33,153,164 | 2,936,507 | SH | DFND | 1 | 2,936,507 | 0 | 0 | |
| BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 30,000,001 | 3,846,154 | SH | DFND | 1 | 3,846,154 | 0 | 0 | |
| CYTOKINETICS, INC | COM | 23282W605 | 62,294,108 | 980,392 | SH | DFND | 1 | 980,392 | 0 | 0 | |
| ZENAS BIOPHARMA, INC. | COM | 055477103 | 45,864,977 | 1,263,150 | SH | DFND | 1 | 1,263,150 | 0 | 0 | |